Parkinson's disease: low-dose haloperidol increases dopamine receptor sensitivity and clinical response.

Parkinsons Dis · 2014 · PMC4258318 · PMID 25506040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Parkinson's Disease Signs and Symptoms The results of the SPES/SCOPA scale on all 16 subjects in the low-dose haloperidol trial indicated a clear trend of improvement of Parkinson's signs and symptoms, starting after one week of treatment, and continuing to improve over baseline throughout the duration of the trial, as shown in Figure 1(a) .

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.